蜂胶酊治疗外耳道炎的临床和实验观察

蜂胶是近年来被广泛应用于医疗上的蜜蜂产品,但应用蜂胶治疗外耳道炎尚未见文献报道。我们应用蜂胶配制成30％蜂胶酊,治疗外耳道炎患者72例,对其药物作用和疗效进行分析,并对外耳道分泌物进行细菌培养,测定蜂胶在肉汤培养基中对外耳道炎常见致病菌的抑菌浓度,观察蜂胶对小白鼠的麻醉镇痛作用,为蜂胶治疗外耳道炎提供有效的实验依据。结果表明蜂胶酊治疗外耳道炎安全可靠。     

土霉素和恩诺沙星治疗猪喘气病的临床疗效观察

目的:本研究通过对比土霉素和恩诺沙星治疗猪喘气病的临床疗效评价适用于生产中治疗猪喘气病的方法.方法:选择病猪90头,随机分为A、B、C三组,每组30头,A组注射土霉素注射液,B组注射恩诺沙星注射液,C组为对照组,不使用药物;另选择30头健康的同一猪场,年龄体重均相近的猪作为健康对照组D组.将第1次给药后15d作为观察期,每组疗程均为3d,分组称重并记录.结果:土霉素和恩诺沙星组临床症状、平均增重、肺部病变比例都显著优于阳性对照组(P<0.05),土霉素治疗效果显著优于恩诺沙星组(P<0.05).结论:土霉素治疗猪喘气病效果显著.     

肠毒唑治疗鸡组织滴虫病的临床观察和体会

组织滴虫病是由火鸡组织滴虫寄生于禽类的盲肠和肝脏引起的一种原虫病。本病特征是肝脏坏死、盲肠发炎呈一侧或双侧肿大为特征,多发于火鸡和雏鸡。由于该病主要侵害盲肠和肝脏故又称盲肠肝炎;又因为可常造成患病火鸡头部血液循     

和营止痛汤治疗闪伤的临床观察与实验研究

用和营止痛汤试治牛、骡、猪的闪伤24例,痊愈19例,有效4例,无效1例,总有效率为95.8%,该方的主要药理作用是抑制闪伤部位肉芽肿的形成,并降低毛细血管的通透性。     

口服凝胶剂治疗犊牦牛腹泻的临床疗效观察和血清生化指标变化

随机选取6~35日龄自然状态下腹泻犊牦牛和正常犊牦牛各12头,对12例腹泻牛进行3d治疗并观察疗效;采集腹泻犊牛治疗前、后及8头正常犊牛血清,同时对剩余4头正常犊每天饲喂该药剂并采集血清分析。结果显示口服凝胶剂对犊牦牛临床腹泻的治愈率为75%(9/12),总有效率达到91.67%(11/12)。血清生化结果显示,各组间Mg2+和CRE差异均不显著(P0.05);血清CRP在腹泻犊牛中显著高于正常组(P0.05)。腹泻治疗前组血清中Ca2+、Cl-、Na+、血清P、TP、ALB、ALP、ALT和AST均显著低于正常对照组(P0.05);治疗后组血清中Ca2+、ALB、ALT、AST较治疗前组显著升高(P0.05),且血清Ca2+、ALB与正常对照组无显著差异(P0.05)。正常犊牛饲喂药剂前后血清中AST、ALP、ALT活性物无显著差异(P0.05)。结果表明,口服凝胶剂对治疗犊牦牛腹泻有效,对正常犊牦牛无不良影响;正常犊牦牛与腹泻犊牛血清生化存在差异。     

口服凝胶剂治疗犊牦牛腹泻的临床疗效观察和血清生化指标变化

目的:探究口服凝胶剂治疗犊牦牛腹泻的临床疗效观察和血清生化指标变化.方法:选择15-30日的腹泻犊耗牛30头,正常的犊耗牛30头,对患有腹泻的犊耗牛进行治疗,治疗周期为一个星期,对治疗的30头犊耗牛的血清收集,然后收集15头正常的犊耗牛的血清,将剩余的15头正常的犊耗牛每天喂治疗腹泻的药物,3天后收集其血清,将观察的血清水平和临床效果制成表格,便于统计和观察.结果:口服凝胶剂对犊耗牛腹泻治疗的效果比较显著,腹泻犊耗牛的血清明显高于正常的犊耗牛(P<0.05),60头犊耗牛之间的差异具有明显的统计学意义(P<0.05).结论:通过对腹泻犊耗牛口服凝胶剂的观察,可以看出口服凝胶剂对腹泻犊耗牛的治疗效果显著,而且不会对正常的犊耗牛产生不良的影响,腹泻犊耗牛与正常犊耗牛的血清生化存在一定的差别,口服凝胶剂治疗犊耗牛的腹泻值得推广使用.     

普通级比格犬蠕形螨病的流行病学及临床症状观察

对２９只普通级比格犬的蠕形螨病进行了流行病学及临床症状观察，结果发现该品种犬蠕形螨病的发生具有明显的家族聚集性，怀孕和哺乳犬以及较多发病，病变均从下腹部开始，并迅速蔓延到胸腹部、下颌、面部、四肢至全身，病变部位与健康部位界线不明显。病变部位的小丘疹以毛囊为中心，感染化脓后内含大量蠕形螨的成虫、幼虫和虫卵，同时也可以查到大量的葡萄球菌、链球菌和杆菌，病犬一般无瘙痒症状。     

猪胆囊壁组织用于兔体内组织修复和粘贴止血的实验观察

以猪胆囊壁组织作为生物膜,用ZT胶粘合的方法,修补兔食管壁人造缺损创10例,对兔肝、脾人工致伤断面进行粘贴止血15个样本。结果,前者成功7例,食管壁缺损创得到修复,愈合良好,且无食管狭窄现象;后者15个样本的止血效果都很确实,并对创面起到了保护作用,有利于创面的愈合。     

山羊毛霉菌病临床与病理学观察

以１０７个／ｍｌ微小根毛霉（Ｒｈｉｚｏｍｕｃｏｒｐｕｓｉｌｕｓ）孢囊孢子悬液颈静脉接种２月龄山羊,每只５ｍｌ,每日１次,连续３日,经８８ｄ观察３／４只山羊死亡。病羊临床表现精神沉郁,消瘦,体温升高,腹泻,后肢瘫痪,白细胞总数及嗜中性白细胞成倍增加,全血ＧＳＨ－ＰＸ活性降低,Ｓ－ＧＯＴ、Ｓ－ＧＰＴ和ＡＫＰ活性升高,血清胆固醇值上升,但以上各项血液生化指标变化与对照羊相比差异不显著（ｐ＞０．０５）。病理变化为全身扩散性毛霉菌病,其典型病变在肺脏,整个肺脏遍布灰白色圆形小结节。镜险肺结节中心为毛霉菌丝或碎片,周围淋巴细胞、单核细胞包绕。腿肌大部分肌束呈凝固性坏死,周围微血管内形成血栓     

SLOW RELEASE CISPLATIN COMBINED WITH RADIATION FOR THE TREATMENT OF CANINE NASAL TUMORS

Thirteen dogs with malignant tumors of the nasal cavity were treated with a combination of slow release cisplatin and megavoltage radiation. Radiation was delivered on a Monday through Friday schedule using a 6 MV linear accelerator. The median total dose was 49.5 Gy (range 49.5-56 Gy). Cisplatin was given using an open-cell polylactic acid polymer, impregnated with the drug and implanted intramus-cularly at a distant site, as a slow release delivery system (OPLAn-Pt [THM Biomedical, Inc]). The median dose used was 60 mg/m2 (range 60–100 mg/m2). When combined with radiation, this delivery system caused no systemic drug toxicity, and a local tissue reaction was seen in only two dogs. Acute side effects to normal tissue from radiation were not enhanced, as measured by subjective assessment. When compared to a group of historical controls that received radiation without OPLA-Pt, the dogs that received combined radiation and cisplatin had longer overall survival times, with a median of 580 days. The control group had a median survival of 325 days. Previously reported median survival times for comparable megavoltage radiation treatment range from 6 to 13 months. Some dogs in both groups also received adjubant chemotherapy but this did not influence survival time. By multivariate analysis, only the use of OPLA-Pt was found to significantly influence survival, with a p value of p = 0.023. Mega-voltage radiation and slow release cisplatin appears to be a well tolerated combination that may favorably affect survival of dogs with nasal tumors.     

COMBINATION OF RADIATION THERAPY AND FIROCOXIB FOR THE TREATMENT OF CANINE NASAL CARCINOMA

Carcinomas represent two‐thirds of canine nasosinal neoplasms. Although radiation therapy (RT) is the standard of care, the incidence of local recurrence following treatment is high. Cyclooxygenase‐isoform‐2 (COX‐2) is expressed in 71–95% of canine nasal carcinomas and has been implicated in tumor growth and angiogenesis. Accordingly, COX‐2 inhibition seems rational to improve outcome. Dogs with histologically confirmed, previously untreated nasal carcinomas were randomized to receive the combination of a selective COX‐2 inhibitor (firocoxib) and palliative RT (Group 1) or RT and placebo (Group 2). Patients were regularly monitored with blood tests, urinalysis, and computed tomography. Pet owners were asked to complete monthly a quality‐of‐life questionnaire. Twenty‐four dogs were prospectively enrolled. According to Adams modified system, there were five stage 1, five stage 2, three stage 3, and 11 stage 4 tumors. Two dogs had metastases to regional lymph nodes. Median progression‐free interval and overall survival were 228 and 335 days in Group 1 (n = 12) and 234 and 244 days in Group 2 (n = 12). These differences were not statistically significant. The involvement of regional lymph nodes was significantly associated with progression‐free interval and overall survival (P = 0.004). Quality of life was significantly improved in Group 1 (P = 0.008). In particular, a significant difference was observed for activity and appetite. Although not providing a significant enhancement of progression‐free interval and overall survival, firocoxib in combination with RT is safe and improved life quality in dogs with nasal carcinomas.